1. Qidu Pharma’s Osowei® - Omeprazole Sodium Bicarbonate Dry Suspension (I) Approved for Market Launch
2.Jisu® - Sodium Bicarbonate Injection (all specifications) pass evaluation, marking Qidu Pharma’s integrated development of APIs + formulations.
3.Qidu Pharma’s Antitumor Drug Yinite® - Ibrutinib Capsules Approved for Production
4.Qidu Pharma’s New Anti-Anaerobic Drug Morinidazole API and Injection Approved for Market Launch
5.Dihuanxin™ - Ciprofloxacin Lactate and Sodium Chloride Injection Passes Consistency Evaluation
6.Qiheng® - Compound Sodium Acetate Ringer’s Injection Passes National Consistency Evaluation
7.Qinengtai® - Pentoxifylline Injection Approved for Market Launch and Deemed to Pass Consistency Evaluation
8.Anpulan® - Lanthanum Carbonate Chewable Tablets Approved for Market Launch and Deemed to Pass Generic Drug Consistency Evaluation
9.Puruitai® - Paracetamol Tablets Approved for Market Launch and Deemed to Pass Consistency Evaluation
Recommended reading
-
January 20, 2025Top Ten Events of Qidu Pharmaceutical Group in 2025 Announced
-
June 17, 2026Qidu Pharma’s intelligent production project for oral preparations with an annual capacity of 10 billion tablets/granules passed the GMP on-site inspection.
-
June 25, 2026Qidu Biotech Approved to Establish "Zibo (Qidu) Cell Preparation Center and Tissue Cell Bank"
-
June 23, 2026Zheng Jiaqing was honored as a National Model Worker
-
June 23, 2026Qidu Pharma was designated as one of the “National Outstanding Excellence-Level Smart Factories”
-
June 23, 2026Qidu Pharma was included in the “Shandong Top 100 Private Enterprises” series of rankings.
-
June 23, 2026Qidu Pharma was listed among China’s top 100 pharmaceutical companies by main business revenue.